DEF: Mangoceuticals Seeks Stockholder Approval for Key Proposals Including Series B Amendment and Equity Incentive Plan

Mangoceuticals is convening a special meeting of stockholders to vote on proposals including amendments to the Series B Convertible Preferred Stock, adoption of the Second Amendment to the Equity Incentive Plan, and other corporate governance matters.

Summary

• Mangoceuticals, Inc. is holding a special meeting on March 17, 2025, to seek stockholder approval for several key proposals.
• The primary proposals include amending the Series B Convertible Preferred Stock to fix the conversion rate and floor price at $1.50 per share, remove dividend accrual, and exclude Mango & Peaches Corp. from the definition of Change of Control Transaction.
• Stockholders will also vote on adopting the Second Amendment to the 2022 Equity Incentive Plan, which increases the number of shares available for issuance to 10,000,000 and provides for automatic annual increases.
• Additionally, stockholders will consider approving the issuance of shares of common stock and Series A Super Majority Voting Preferred Stock of Mango & Peaches to CEO Jacob Cohen.
• The board of directors unanimously recommends voting for all proposals.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining proposals for stockholder vote. The sentiment is neutral to slightly positive, reflecting the board's recommendation to approve the proposals and the potential benefits they could bring to the company.

Positives

• Amending the Series B Preferred Stock could facilitate conversions and simplify the capital structure.
• The increased share reserve in the Equity Incentive Plan could help attract, retain, and motivate key employees and directors.
• The proposed equity compensation for the CEO could align his interests with the long-term success of Mango & Peaches.

Negatives

• Amending the Series B Preferred Stock could lead to significant dilution for existing stockholders, with a potential issuance of 1,872,934 shares.
• Issuing shares of Mango & Peaches to the CEO could give him majority control over a significant portion of the company's assets.
• If Proposal 3 is not approved, the company may be forced to compensate Mr. Cohen in cash for services he provides to Mango & Peaches and he will not be able to convert the M&P Bonus into shares of Mango & Peaches, thereby requiring M&P to pay such bonus, which may total up to $10,000,000, in cash.

Risks

• Failure to approve the Series B amendment could hinder conversions and potentially trigger events of default under the existing terms.
• The issuance of additional shares could negatively impact the trading price of the company's common stock.
• The concentration of ownership in Mango & Peaches could limit the company's ability to undertake transactions with the subsidiary without the CEO's approval.
• If Proposal 3 is approved but Proposal 1 isnt, it is possible that the issuance of the M&P Common Shares, M&P Series A Shares and the M&P Bonus Shares to Mr. Cohen may trigger an event of default under the Series B Designation.

Future Outlook

The company is focused on growing its mens wellness telemedicine services and products, particularly in areas such as erectile dysfunction, hair growth, hormone therapies, and weight management. The company expects to issue additional securities in the future and such issuances are expected to further dilute the Companys ownership in Mango & Peaches.

Management Comments

• Our Board of Directors encourages your participation in Mangoceuticals, Inc.'s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement.
• Your vote and participation in our governance is very important to us.

Industry Context

The document notes the growing sector of men's wellness telemedicine services and products, particularly in areas like erectile dysfunction, hair growth, hormone therapies, and weight management, suggesting the company operates within this expanding market.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• Without more information, it is difficult to assess the company's performance against global benchmarks.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution and changes in control.
• Employees could be affected by changes to the equity incentive plan.
• The outcome of the vote could influence the company's financial condition and future operations.

Next Steps

• Stockholders are urged to review the proxy statement and vote on the proposals.
• The company will file the final voting results with the SEC within four business days following the special meeting.

Key Dates

Keywords

proxy statement, stockholder meeting, Series B Preferred Stock, equity incentive plan, Mango & Peaches, Jacob Cohen, conversion price, dilution, corporate governance